Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

4.63
-0.1800-3.74%
Post-market: 4.58-0.0500-1.08%19:47 EDT
Volume:1.45M
Turnover:6.75M
Market Cap:279.94M
PE:-1.00
High:4.85
Open:4.85
Low:4.57
Close:4.81
52wk High:9.94
52wk Low:4.27
Shares:60.46M
Float Shares:47.66M
Volume Ratio:0.84
T/O Rate:3.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6291
EPS(LYR):-3.7413
ROE:-77.81%
ROA:-22.38%
PB:1.27
PE(LYR):-1.24

Loading ...

Vanda Presents New Gemini-1 Data on Imsidolimab in Generalized Pustular Psoriasis at EADV 2026

Reuters
·
Yesterday

Vanda's Late-Stage Trial of Sleep Disorder Drug Meets Primary Goal

MT Newswires Live
·
Sep 30

Vanda Pharmaceuticals reports results from pivotal Phase III study of HETLIOZ

TIPRANKS
·
Sep 30

Vanda Pharmaceuticals up 33% after Phase 3 Hetlioz study met primary endpoint

TIPRANKS
·
Sep 30

Vanda Says Phase III Trial Shows Hetlioz Advances Sleep Onset in Delayed Sleep-Wake Phase Disorder

Reuters
·
Sep 30

Vanda Plans FDA sNDA Filing for Hetlioz in Delayed Sleep-Wake Phase Disorder

Reuters
·
Sep 30

Vanda Pharmaceuticals - no New Safety Signals Identified in Phase Iii Study for Hetlioz

THOMSON REUTERS
·
Sep 30

Vanda Pharmaceuticals - Phase Iii Study Met Primary Endpoint with 37.1 Minute Sleep Onset Shift vs Placebo

THOMSON REUTERS
·
Sep 30

Vanda Pharmaceuticals Announces Positive Phase Iii Results for Hetlioz®(Tasimelteon) in Delayed Sleep-Wake Phase Disorder

THOMSON REUTERS
·
Sep 30

Vanda Pharmaceuticals Inc : Oppenheimer Initiates Coverage with Outperform Rating; Price Target $10

THOMSON REUTERS
·
Sep 23

BetterLife Pharma Names Charles Duncan Audit Committee Chair, Appoints Him Director

Reuters
·
Sep 11

Vanda Pharma to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 03

Vanda Says EU Grants Orphan Drug Status to Imsidolimab for Generalized Pustular Psoriasis

Reuters
·
Aug 24

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

THOMSON REUTERS
·
Aug 24

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Vanda (VNDA) and AbCellera Biologics (ABCL)

TIPRANKS
·
Aug 10

B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating

MT Newswires Live
·
Aug 10

Vanda Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 10

Vanda (VNDA) Gets a Buy from Cantor Fitzgerald

TIPRANKS
·
Aug 08

Praxis Precision Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 06

Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates

Reuters
·
Aug 06